• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·8049.HK
Share

Jilin Province Huinan Changlong Bio-pharmacy Company Limited Stocks

HK$ 2.42Last Updated 24.06.2026

Issuer Rating

4/7
Performance

Strong

Risk

High

Recommendation

Hold

Market Cap

HK$ 191.59M

HK$ 2.42
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.06.2026 03:02

Bain has revised its forecast for luxury market growth downward. Why is it talking about a recovery in the industry?

26.06.2026 01:29

Market Split: Nasdaq Falls for the Fourth Consecutive Day Despite a Rally in Chipmakers

26.06.2026 00:48

Qualcomm will produce AI chips for Meta's data centers. Its stock soared

26.06.2026 00:13

Citigroup raised its price target for SanDisk by 23%. Its stock has already risen 860% in 2026

25.06.2026 23:22

Iran Attacked a Cargo Ship in the Strait of Hormuz — WSJ. Oil Prices Rise

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026